GILEAD
Creating Possible

Q123 Financial Results

April 27, 2023

Forward-Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead's business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales, and Gilead's ability to effectively manage the global supply and distribution of Veklury; Gilead's ability to achieve its anticipated full year 2023 financial results, including as a result of potential adverse revenue impacts from COVID-19 and potential revenues from Veklury; Gilead's ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including Gilead's ability to identify suitable transactions as part of its business strategy and the risk that Gilead may not be able to complete any such transaction in a timely manner or at all, including the possibility that a governmental entity or regulatory body may delay or refuse to grant approval for the consummation of the transaction; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead's product candidates or the product candidates of Gilead's strategic partners; Gilead's ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead's ability to receive regulatory approvals in a timely manner or at all, and the risk that any such approvals may be subject to significant limitations on use; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products, including the risk that Kite may be unable to increase its manufacturing capacity, timely manufacture and deliver its products or produce an amount of supply sufficient to satisfy demand for such products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Contents

Gilead Q123 Key Takeaways

Financial Results

- Total Product Sales, excl. Veklury, +15% YoY to $5.7B, with strong HIV and Oncology growth
- Total HIV +13% YoY strong growth amid seasonal dynamics, with Biktarvy +24% YoY to $2.7B
- Oncology +59% YoY to $670M driven by Cell Therapy and Trodelvy
- Operating expenses driven by higher clinical trial activities, including 22 Phase 3 trials[1]

Regulatory Activity

- Trodelvy approved in U.S. for pre-treated HR+/HER2- mBC
- Continue to expect MAA decision on Trodelvy for pre-treated HR+/HER2- mBC in 2H23

Pipeline Execution

- Positive Phase 3 ZUMA-7 overall survival data shared for Yescarta
- Positive Phase 1b data for lenacapavir plus bNAbs at CROI
- Positive Phase 1 data for obeldesivir (GS-5245) shared at ECCMID
- 10 trials achieved FPI, including OAKTREE for obeldesivir and ZUMA-23 for 1L LBCL
- Completed Tmunity acquisition, adding solid tumor programs, manufacturing & technology platform

1. Gilead-sponsored trials (excluding ISRs and regional bridging studies). ALL – acute lymphoblastic leukemia, bNAb – Broadly neutralizing antibodies, CROI - Conference on Retroviruses and Opportunistic Infections, ECCMID – European Congress of Clinical Microbiology & Infectious Diseases, FPI – First patient in (patient screening + consent), HR+/HER2- mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, MAA - Type II variation Marketing Authorization Application, LBCL - large B-cell lymphoma, TAF – tenofovir alafenamide, sBLA – supplemental Biologics License Application, PLWH – People living with HIV, r/r – Relapsed/refractory, TNBC – Triple negative breast cancer. Obeldesivir is an investigational product; it is not approved anywhere globally and its safety and efficacy are not established.

2023 Focus: Select Key Catalysts Across Portfolio

1H23

Completed On Track

Program	Trial	Indication	Update	Status
Trodelvy	TROPiCS-02	HR+/HER2- mBC	sBLA decision	✓
	EVOKE-03	1L NSCLC	Phase 3 FPI	✓
	ASCENT-05	Adjuvant TNBC	Phase 3 FPI	✓
Domvanalimab	ARC-7	1L NSCLC	Phase 2 update	○

Program	Trial	Indication	Update	Status
Yescarta	ZUMA-23	1L HR LBCL	Phase 3 FPI	✓
	ZUMA-24	2L LBCL OPT	Interim phase 2 update	○
Obeldesivir	OAKTREE	COVID-19 standard risk	Phase 3 FPI	✓
Len / isl oral	NCT05052996	HIV LA VS	Phase 2 FPI (restart)	✓

2H23

Program	Trial	Indication	Update	Status
Trodelvy	TROPiCS-02	HR+/HER2- mBC	MAA decision	○
	ASCENT-07	HR+/HER2- chemo-naïve mBC	Phase 3 FPI	○
Etrumadenant	ARC-6	mCRPC	Interim phase 2 update	○
	ARC-9	mCRC	Interim phase 2 update	○
Magrolimab	ENHANCE	1L HR MDS	Interim phase 3 update	○

Program	Trial	Indication	Update	Status
Len / bic oral	ARTISTRY-1	HIV VS TE	Phase 2 update	○
Lenacapavir	PURPOSE 3	HIV PrEP	Phase 2 FPI	○
Lenacapavir	PURPOSE 4	HIV PrEP	Phase 2 FPI	○
Bulevirtide	MYR204	HDV Finite Tx	Phase 2 update	○
Tilpisertib fosmecarbil	PALEKONA	Ulcerative Colitis	Phase 2 FPI	○

Bic – bictegravir, FPI – first patient in (patient screening + consent), HDV – hepatitis D virus, HIV - human immunodeficiency virus, HR – high risk, HR+/HER2- mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, ISL – islatravir (Merck's), LA – long acting, LBCL - large B-cell lymphoma, Len – lenacapavir, MAA - marketing authorization application, mCRC – metastatic colorectal cancer, mCRPC – metastatic castrate-resistant prostate cancer, MDS – myelodysplastic syndrome, NSCLC – non-small cell lung cancer, OPT – outpatient, PrEP - pre-exposure prophylaxis, sBLA – supplemental biologics license application, TE – treatment experienced, TNBC - triple-negative breast cancer, Tx – treatment, VS – virally suppressed.

GILEAD
Creating Possible

Commercial Results & Market Dynamics

Johanna Mercier

Chief Commercial Officer

Robust HIV and Oncology Growth YoY in Q123



(in $M except as otherwise noted)

$4.2B **HIV Product Sales**
Up 13% YoY, down 12% QoQ

$670M **Oncology Product Sales**
Up 59% YoY, up 9% QoQ

$5.7B **Total Product Sales excluding Veklury**
Up 15% YoY, down 9% QoQ

$6.3B **Total Product Sales**
Down 3% YoY, down 14% QoQ

Note: Liver Disease includes: chronic hepatitis B virus, chronic hepatitis C virus and chronic hepatitis D virus. YoY reflects Q123 vs Q122 and QoQ reflects Q123 vs Q422.

HIV: Strong Demand Amid Seasonal Dynamics



Solid Q123 Growth of +13% YoY

- **YoY** due to favorable pricing dynamics, higher demand and lower inventory draw-down
- **QoQ** decline due to seasonal inventory and pricing dynamics, offset by higher demand
- Sunlenca for HTE now available in the U.S. and Europe

Market Growth Continues YoY

- U.S. treatment market up ~2% with Europe up ~4%
- U.S. PrEP market up ~19%

HTE – heavily treatment-experienced, PrEP – pre-exposure prophylaxis. YoY reflects Q123 vs Q122 and QoQ reflects Q123 vs Q422. Sunlenca (lenacapavir) injection 463.5 mg/1.5 mL.

Leadership Across HIV Treatment & PrEP

Q123 sales: $2.7B; +24% YoY, -8% QoQ

>46%
U.S. Treatment Market Share

3%
U.S. Market Share Gain YoY

+24% YoY due to higher demand and favorable pricing and inventory dynamics

-8% QoQ due to seasonal inventory and pricing dynamics, offset by higher demand

Q123 sales: $449M; +20% YoY, -16% QoQ

>40%
U.S. PrEP Market Share

+14%
U.S. Descovy for PrEP Demand Growth YoY

+20% YoY due to higher demand and favorable pricing

-16% QoQ due to seasonal pricing and inventory dynamics, offset by higher demand

Note: YoY reflects Q123 vs Q122 and QoQ reflects Q123 vs Q422. Biktarvy (bictegravir 50 mg, emtricitabine 200 mg, tenofovir alafenamide 25 mg) tablets. Descovy (emtricitabine 200 mg, tenofovir alafenamide 25 mg) tablets. PrEP – pre-exposure prophylaxis.

Liver Disease: Maintaining Position in Viral Hepatitis



EPCLUSA® sofosbuvir/velpatasvir 400 mg/100 mg tablets

SOVALDI® SOFOSBUVIR 400 mg TABLETS

Vemlidy® tenofovir alafenamide 25mg tablets

HARVONI® ledipasvir/sofosbuvir 90 mg/400 mg tablets

VOSEVI® sofosbuvir 400 mg/velpatasvir 100 mg voxilaprevir 100 mg tablets

HEPCLUDEX®

Q123 sales +6% YoY; -3% QoQ

- **+6% YoY** primarily due to higher demand and timing of DOC HCV purchases in the U.S.
- **-3% QoQ** primarily due to lower HBV-related channel inventory in the U.S., partially offset by timing of HCV orders in Europe

HCV includes Epclusa, the authorized generic version of Epclusa, Harvoni, the authorized generic version of Harvoni, Sovaldi and Vosevi. HBV includes Hepsera (adefovir dipivoxil), Vemlidy (tenofovir alafenamide), and Viread (tenofovir disoproxil fumarate). HDV includes Hepcludex (bulevirtide). Note: Hepcludex is conditionally authorized by the European Commission for treatment of chronic HDV. Its safety and efficacy have not been established in the United States or in other regions where it has not received regulatory approval. YoY reflects Q123 vs Q122 and QoQ reflects Q123 vs Q422. DOC – Department of Corrections.

Veklury: Solid Share Despite Lower Hospitalizations



Veklury® remdesivir 100 MG FOR INJECTION

>50%

U.S. hospitalized patients treated for COVID[1]

~13M

People treated with remdesivir to date[2]

- Obeldesivir[3] Phase 3 trials underway in non-hospitalized patients with COVID-19 who are deemed high-risk or standard-risk

1. Source: Premier and HealthVerity CDM data. 2. Represents number of treatments of Veklury or remdesivir made available by Gilead, its distributors and voluntary licensees. 3. GS-5245; Obeldesivir is an investigational product; it is not approved anywhere globally and its safety and efficacy are not established.

Trodelvy: Expanding Breast Cancer Options



TRODELVY®
sacituzumab govitecan

$222M
Sales in Q123

+52%
YoY Growth

+14%
QoQ Growth

- Solid U.S. demand, up 7% QoQ
- FDA approval received for pre-treated HR+/HER2- mBC in February 2023
- EC decision expected in 2H23

EC – European Commission, HR+/HER2- mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. Note: YoY reflects Q123 vs Q122 and QoQ reflects Q123 vs Q422.

Cell Therapy: Demand Drives YoY Growth



YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion

Q123 sales +70% YoY; Up 6% QoQ

- YoY growth driven by higher demand across 2L and 3L R/R large B-cell lymphoma, as well as favorable pricing dynamics in Europe

TECARTUS® (brexucabtagene autoleucel) Suspension for IV infusion

Q123 sales +40% YoY; +8% QoQ

- YoY growth driven by higher demand for R/R mantle cell lymphoma and R/R adult acute lymphoblastic leukemia

R/R – Relapsed or refractory. Note: YoY reflects Q123 vs Q122 and QoQ reflects Q123 vs Q422.

GILEAD
Creating Possible

CMO Updates

Merdad Parsey, MD, PhD

Chief Medical Officer

Gilead Demonstrates Leadership in HIV at CROI

83 Virology Abstracts at CROI 2023[1]

3 HIV Oral Presentations at CROI 2023

13 Clinical Programs in HIV

	Pre-Clinical	Clinical Trials	Real World Analysis
HIV Prevention	● ***In vivo* macaque model** Lenacapavir		● 8+ Years Pooled Analysis TDF/emtricitabine
HIV Treatment	● ***In vitro cross-resistance model*** Lenacapavir and islatravir	● **Phase 1b** Lenacapavir + TAB + ZAB *+ additional lenacapavir analysis from CAPELLA and CALIBRATE*	
HIV Cure	● ★ ***In vivo* non-human primates** HIV Vaccines + lefitolimod + TAB + bNAb	● ★ **Phase 2 AELIX-003** HIV Vaccines + vesatolimod	

● Q6M Dosing ● QW Dosing ● Daily Oral ● Finite Regimen ★ Late-Breaker

1. Gilead-led and supported. bNAb – broadly neutralizing antibody, CROI – Conference on Retroviruses and Opportunistic Infections, TAB – teropavimab, TDF – tenofovir disoproxil fumarate, ZAB – zinlirvimab. Islatravir, lefitolimod, teropavimab, vesatolimod, and zinlirvimab are investigational products; their use alone or in combination with other agents have not been approved anywhere globally and their safety and efficacy have not been established.

Committed to Continued Efforts in COVID-19

Veklury® remdesivir 100 MG FOR INJECTION | EVERY DAY COUNTS

Real World Analyses

- Reduced 30-day hospital readmission across variants[1]
- Improves 14-day and 28-day survival, including in immunocompromised patients[2]

Obeldesivir

(GS-5245)

BIRCH + OakTree

High-Risk

~45%

Diagnosed patients with COVID-19 at high-risk[3]

Standard-Risk

~55%

Diagnosed patients with COVID-19 at standard-risk[4]

2 ongoing registrational Phase 3 studies

OAKTREE FPI in Q123

Study Dosing: Obeldesivir one tablet, twice-daily for 5 days

Note: Obeldesivir is an investigational product; it is not approved anywhere globally, and its safety and efficacy are not established. 1. Pre-delta, Delta, and Omicron Variants from 2020-2022. 2. In patients who received Veklury, in the first two days of hospital admission. Real world analyses of Veklury from other sources are ongoing and may vary in their results or conclusions. 3. Defined as patients with 1+ (if unvaccinated) or 2+ (if vaccinated) risk factors, such as >50 years of age, cardiovascular disease, and chronic lung disease. 4. Defined as patients without underlying medical conditions associated with higher risk for severe COVID-19 per CDC guidelines. FPI – first patient in (patient screening + consent).

Trodelvy: Cornerstone of Solid Tumor Portfolio

TRODELVY®
sacituzumab govitecan

Breast Cancer

New FDA Approval

- FDA Approval in Pre-treated HR+/HER2- mBC and EC Decision Expected 2H23
- Now Approved in 47 Markets for mTNBC

5 Ongoing Phase 3 Trials

NSCLC

Expanding NSCLC Program[1]

- EVOKE-01 (2-3L) Data in 2024
- EVOKE-03 (1L) FPI

2 Ongoing Phase 3 Trials

Bladder Cancer

ASCO GU Data Update

- TROPHY Cohort 1 Data Update
- TROPHY Cohort 2-3 Primary Analysis

1 Ongoing Phase 3 Trials

1. Trodelvy is not approved in NSCLC. ASCO GU – American Society of Clinical Oncology Genitourinary Cancers Symposium, EC – European Commission, FPI – first patient in (patient screening + consent), HR+/HER2- mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, mTNBC – Metastatic triple-negative breast cancer, NSCLC – Non-small cell lung cancer. Note: The use of Trodelvy for the treatment of NSCLC is investigational; Trodelvy is not approved for this use and the efficacy and safety of this use have not been established.

Cell Therapy Portfolio Continues to Expand

Key Updates:

Expanding into Multiple Myeloma
ARCELLX Transaction Closed Jan 2023

Investment in Rapid Manufacturing & Novel CAR T Technology
TMUNITY Transaction Closed Feb 2023

ZUMA-7: 2L LBCL
Yescarta Shows 5-Year OS Benefit

ZUMA-24: 2L LBCL OPT
Interim Phase 2 Update Expected in Q223



1. This clinical program is currently led by Arcellx. 2. These clinical programs are led by Tmunity, which was acquired by Kite. LBCL – large B-cell lymphoma, OPT – outpatient, OS – overall survival.

GILEAD | Kite

2023 Focus: Select Key Catalysts Across Portfolio

1H23

✓ Completed ○ On Track

Program	Trial	Indication	Update	Status
Trodelvy	TROPiCS-02	HR+/HER2- mBC	sBLA decision	✓
	EVOKE-03	1L NSCLC	Phase 3 FPI	✓
	ASCENT-05	Adjuvant TNBC	Phase 3 FPI	✓
Domvanalimab	ARC-7	1L NSCLC	Phase 2 update	○

Program	Trial	Indication	Update	Status
Yescarta	ZUMA-23	1L HR LBCL	Phase 3 FPI	✓
	ZUMA-24	2L LBCL OPT	Interim phase 2 update	○
Obeldesivir	OAKTREE	COVID-19 standard risk	Phase 3 FPI	✓
Len / isl oral	NCT05052996	HIV LA VS	Phase 2 FPI (restart)	✓

2H23

Program	Trial	Indication	Update	Status
Trodelvy	TROPiCS-02	HR+/HER2- mBC	MAA decision	○
	ASCENT-07	HR+/HER2- chemo-naïve mBC	Phase 3 FPI	○
Etrumadenant	ARC-6	mCRPC	Interim phase 2 update	○
	ARC-9	mCRC	Interim phase 2 update	○
Magrolimab	ENHANCE	1L HR MDS	Interim phase 3 update	○

Program	Trial	Indication	Update	Status
Len / bic oral	ARTISTRY-1	HIV VS TE	Phase 2 update	○
Lenacapavir	PURPOSE 3	HIV PrEP	Phase 2 FPI	○
Lenacapavir	PURPOSE 4	HIV PrEP	Phase 2 FPI	○
Bulevirtide	MYR204	HDV Finite Tx	Phase 2 update	○
Tilpisertib fosmecarbil	PALEKONA	Ulcerative Colitis	Phase 2 FPI	○

Bic – bictegravir, FPI – first patient in (patient screening + consent), HDV – hepatitis D virus, HIV - human immunodeficiency virus, HR – high risk, HR+/HER2- mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, ISL – islatravir (Merck's), LA – long acting, LBCL - large B-cell lymphoma, Len – lenacapavir, MAA - marketing authorization application, mCRC – metastatic colorectal cancer, mCRPC – metastatic castrate-resistant prostate cancer, MDS – myelodysplastic syndrome, NSCLC – non-small cell lung cancer, OPT – outpatient, PrEP - pre-exposure prophylaxis, sBLA – supplemental biologics license application, TE – treatment experienced, TNBC - triple-negative breast cancer, Tx – treatment, VS – virally suppressed.

GILEAD
Creating Possible

Financial Results

Andrew Dickinson

Chief Financial Officer

Q123 Strong Base Sales Growth of 15% YoY



Total Product Sales down 3% YoY

- Veklury decline partially offset by base business growth
- Net of hedges, FX negatively impacted Total Product Sales by ~$106M YoY, or ~2%

Product Sales excl. Veklury up 15% YoY

- Double-digit growth in HIV and Oncology
- Excluding FX headwind of ~$81M, Product Sales excluding Veklury was up 16% YoY

First Quarter Non-GAAP Data

In millions, except percentages and per share amounts	Q122	Q123	YoY Change
COGS	825	871	-
Product Gross Margin	87%	86%	-
R&D[1]	1,150	1,439	+25%
Acquired IPR&D[1]	8	481	N/M
SG&A	1,083	1,318	+22%
Non-GAAP Costs and Expenses	**$3,066**	**$4,109**	**34%**
Non-GAAP Operating Income	**$3,524**	**$2,243**	**-36%**
Operating Margin	53%	35%	
Effective Tax Rate	18%	19%	
Non-GAAP Net Income	**$2,676**	**$1,725**	**-36%**
Non-GAAP Diluted EPS	$2.12	$1.37	-35%
Shares used in per share calculation-diluted	**1,262**	**1,261**	

Expenses

- **R&D** primarily driven by increased clinical activities
- **Acquired IPR&D** in Q123 includes expenses associated with Tmunity, Arcellx and Nurix transactions
- **SG&A** primarily driven by Oncology commercial expansion and investments, higher BPD fee and corporate activities

Operating Margin & EPS

- Decreases reflect higher operating expenses and lower revenues, primarily due to Veklury

1. Prior periods are revised to conform to these new presentations. BPD – Branded Prescription Drug fee.

2023 Guidance

	2 February 2023	27 April 2023
Total Product Sales	$26.0B - $26.5B	No change
Product Sales ex-Veklury	$24.0B - $24.5B	No change
Veklury Sales	~$2.0B	No change
Non-GAAP		
Product Gross Margin	86%	No change
R&D Expense	High single-digit % growth	Low double-digit % growth
Acquired IPR&D	$0.7B	No change
SG&A Expense	Low single-digit % decline	No change
Operating Income	$11.0B - $11.6B	No change
Effective Tax Rate	~20%	No change
Diluted EPS	$6.60 - $7.00	No change
GAAP Diluted EPS	$5.30 - $5.70	$4.75 - $5.15

Product Sales Guidance Unchanged

- Base business growth of 4% to 6% YoY

Non-GAAP Operating Expenses

- Increased investment R&D to reflect greater clinical trial activities

GAAP Diluted EPS

- Update from last quarter reflects additional intangible asset amortization following approval of Trodelvy for pre-treated HR+/HER2- mBC and changes in the fair value of equity investments

This financial guidance excludes the impact of any expenses related to potential acquisitions or business development transactions that have not been executed, fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts. This guidance is subject to a number of risks and uncertainties. See Forward-Looking Statements on page 2. Please refer to the accompanying press release and for GAAP to non-GAAP reconciliations. mBC – metastatic breast cancer.

Capital Priorities Unchanged: Returned ~$1.4B in Q1

$969M

Dividends Paid in Q123

$400M

Shares Repurchased in Q123
4.9M shares at average $82.29

- Continue to invest in our business and R&D pipeline while managing expenses
- Continue ordinary course partnerships and business development transactions
- Grow our dividend
- Repurchase shares to offset dilution and opportunistically reduce share count

GILEAD
Creating Possible

Q&A

Daniel O'Day

Chairman and
Chief Executive Officer

Andrew Dickinson

Chief Financial Officer

Johanna Mercier

Chief Commercial Officer

Merdad Parsey, MD, PhD

Chief Medical Officer

GILEAD
Creating Possible

Appendix

Robust Pipeline with Upcoming Catalysts

61 Clinical stage programs[1] **11** Potential clinical stage opt-in assets



Pipeline shown above as of end of Q1'23. FDA approved medicines shown: Trodelvy® for 2L mUC (accelerated approval) and Trodelvy® for pre-treated HR+/HER2- mBC. 1. Program count does not include potential partner opt-in programs or programs that have received both FDA and EC approval. 2. Conditionally authorized by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. 3. Obeldesivir formerly known as GS-5245. AML - acute myeloid leukemia, axi-cel - axicabtagene ciloleucel, aza - azacitidine, chemo - chemotherapy, dom - domvanalimab, FL - follicular lymphoma, GI - gastrointestinal, HDV - hepatitis delta virus, HIV - human immunodeficiency virus, HR - high risk, HR+/HER2-mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, LBCL - large B-cell lymphoma, MDS - myelodysplastic syndrome, mTNBC - metastatic triple-negative breast cancer, mUC - metastatic urothelial carcinoma, NSCLC - non-small cell lung cancer, PD-L1 - programmed death-ligand 1, pembro - pembrolizumab, PrEP - pre-exposure prophylaxis, TNBC - triple-negative breast cancer, TP53m - tumor protein 53 mutation, TPS - tumor proportion scale, zim - zimberelimab.

Oncology Cell Therapy Pipeline

★ New listing since Q4'22 ▲ Change since Q4'22
● Breakthrough Therapy Designation P PRIME Designation



Pipeline shown above as of end of Q1'23. 1. Global strategic collaboration to co-develop and co-commercialize with Arcellx. ALL - acute lymphocytic leukemia, AML - acute myeloid leukemia, FL - follicular lymphoma, FPI – first patient in (patient screening + consent), HR – high risk, LBCL - large B-cell lymphoma, MM – multiple myeloma, R/R – relapsed/refractory.

Oncology Pipeline 1/2

★ New listing since Q4'22 ▲ Change since Q4'22
● Breakthrough Therapy Designation P PRIME Designation



Pipeline shown above as of end of Q1'23. 1. In collaboration with Merck. 2. In collaboration with Arcus Biosciences. 3. In collaboration with Arcus Biosciences and AstraZeneca. 4. VELOCITY-Lung includes combinations of domvanalimab, etrumadenant, zimberelimab, and sacituzumab govitecan-hziy. 5. EDGE-Lung includes immunotherapy-based combinations of quemliclustat, domvanalimab, and zimberelimab. 6.The FDA granted accelerated approval for Trodelvy® in 2L mUC Apr 2021 based on TROPHY U-01 Phase 1b trial. AA - accelerated approval, Chemo – chemotherapy, FPI - first patient in (patient screening + consent), HNSCC – head and neck squamous cell carcinoma, HR+/HER2-mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, IO - immuno-oncology, MAA – marketing authorization application, mCRPC – metastatic castrate-resistant prostate cancer, mTNBC - metastatic triple-negative breast cancer, mUC - metastatic urothelial carcinoma, NSCLC – non-small cell lung cancer, PD-L1 - programmed death-ligand 1, sBLA – supplemental biologics license application, SG - sacituzumab govitecan-hziy, TNBC - triple-negative breast cancer, TPS – tumor proportion scale.

Oncology Pipeline 2/2

★ New listing since Q4'22 ▲ Change since Q4'22
● Breakthrough Therapy Designation P PRIME Designation



Pipeline shown above as of end of Q1'23. 1. Breakthrough and PRIME designation and Promising Innovative Medicine from MHRA. 2. In collaboration with Arcus Biosciences. 3. Additional MDS and AML cohorts within other ongoing Phase 1b study. AML - acute myeloid leukemia, CCR8 – chemokine Receptor 8, CRC – colorectal cancer, DLBCL - diffuse large B-cell lymphoma, GI – gastrointestinal, HR – high risk, MCL1 – myeloid cell leukemia-1, mCRC – metastatic colorectal cancer, MDS – myelodysplastic syndrome, MM - multiple myeloma, mPDAC - metastatic pancreatic ductal adenocarcinoma, ST – Solid tumor, TP53m - tumor protein 53 mutation, UC - urothelial carcinoma.

Viral Diseases Pipeline

★ New listing since Q4'22 ▲ Change since Q4'22
● Breakthrough Therapy Designation P PRIME Designation



Pipeline shown above as of end of Q1'23. 1. Phase 2 study being conducted in treatment naïve patients to support virologically suppressed indication. 2. Subject to Gilead and Merck co-development and co-commercialization agreement. 3. Non-Gilead sponsored trial(s) ongoing. 4. Teropavimab and zinlirvimab are bNABs. 5. Conditionally authorized by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. BLA – biologics license application, bNAb - broadly neutralizing antibody, FPI – first patient in (patient screening + consent), HBV – hepatitis B virus, HDV – hepatitis delta virus, HIV - human immunodeficiency virus, INSTI - integrase strand transfer inhibitor, LA - long acting, NNRTI - non-nucleoside reverse transcriptase inhibitor, PrEP - pre-exposure prophylaxis, TE – treatment experienced, VS – virologically suppressed.

Inflammatory Diseases Pipeline

New listing since Q4'22 | Change since Q4'22
Breakthrough Therapy Designation | P PRIME Designation

			Phase 1	Phase 2	Phase 3	Filed	Updates since Q4'22
Inflammatory Disease	Tilpisertib fosmecarbil	Inflammatory Bowel Disease					
	Edecesertib	Lupus					
	α4β7 inhibitor (GS-1427)	Inflammatory Bowel Disease					
	BTLA agonist (GS-0272)	Inflammatory Diseases					
Fib-rosis	Cilofexor/firsocostat/semaglutide combination[1]	NASH					
Opt-ins	Galapagos	Inflammatory and Fibrotic Diseases	3 clinical stage programs				

Pipeline shown above as of end of Q1'23. 1. Clinical collaboration with Novo Nordisk. BTLA - B- and T-lymphocyte attenuator, NASH – nonalcoholic steatohepatitis.

GAAP to Non-GAAP Reconciliation of Outstanding Adjusted Debt and Adjusted EBITDA

in billions where applicable	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023
Total Debt, net	$26.21	$26.22	$25.22	$25.23	$25.24
Debt Discounts, Premiums and Issuance Costs	0.17	0.17	0.17	0.16	0.16
Liability related to sale of future royalties[1]	(1.13)	(1.14)	(1.14)	(1.14)	(1.15)
Total Adjusted Debt[1, 2]	**$25.25**	**$25.25**	**$24.25**	**$24.25**	**$24.25**

	Last Twelve Months Ended				
	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023
Net Income attributable to Gilead	$4.52	$4.14	$3.33	$4.59	$5.58
Add: Interest Expense[3] & Other Income (expense), net	1.35	1.46	1.46	1.52	1.58
Add: Tax	1.37	1.44	1.23	1.25	1.73
Add: Depreciation	0.32	0.32	0.32	0.32	0.34
Add: Amortization[4]	2.18	2.18	2.16	2.08	2.05
Add: Acquired in-process research and development expenses[5]	0.11	0.32	0.71	0.84	1.30
Add: In-process research and development impairment	2.70	2.70	2.70	2.70	0.00
Add: Litigation matters[6]	1.25	1.25	1.25	0.00	0.00
Adjusted EBITDA[7,8]	**$13.80**	**$13.80**	**$13.17**	**$13.30**	**$12.58**
Adjusted Debt to Adjusted EBITDA ratio[7, 8]	**~1.83x**	**~1.83x**	**~1.84x**	**~1.82x**	**~1.93x**

1 Represents a funding agreement with RPI Finance Trust that was assumed as part of our acquisition of Immunomedics under which Immunomedics received cash in exchange for perpetual, tiered royalty payments on worldwide sales of Trodelvy. This funding agreement is classified as debt. 2 Adjusted Debt excludes future tax payments related to remaining obligations for the deemed one-time repatriation transition tax from the Tax Cuts and Jobs Act, totaling $3.5 billion as of March 31, 2023. These future tax payments are expected to be $0.9 billion in 2023, $1.2 billion in 2024 and $1.5 billion in 2025. 3 Total interest expense and amortization from all issued debt is expected to be approximately $900 million for full year 2023. 4 Beginning in Q4 2020, includes acquisition-related amortization of inventory step-up charges. 5 Beginning in Q2 2022, the Acquired IPR&D expenses line item on our Condensed Consolidated Statement of Operations was revised to include expenses related to development milestones and other collaboration payments made prior to regulatory approval, which were previously included in R&D expenses line item, as well as initial costs to acquire rights to IPR&D projects with no alternative future use through collaborations, licensing or asset acquisitions. All prior periods presented in our Condensed Consolidated Statement of Operations were recast to reflect this change. For all periods presented, Adjusted EBITDA excludes only initial costs of externally developed IPR&D projects with no alternative future use, acquired directly in a transaction other than a business combination, including upfront payments related to various collaborations and the initial costs of rights to IPR&D projects. 6 Represents a charge related to a legal settlement. 7 Represents the last twelve months of adjusted EBITDA. 8 Adjusted EBITDA and Adjusted Debt to Adjusted EBITDA ratio are non-GAAP performance measures used by our investors and analysts to assess the overall operating performance in the context of financial leverage.